J F Robertson
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
Bonneterre J, Arimidex Writing Committee, Steinberg M, Webster A, Sahmoud T, von Euler M, Thürlimann B, Robertson J, Nabholtz J, Buzdar A, Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92:2247-58.
01.11.2001Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
01.11.2001Cancer 2001; 92:2247-58
Bonneterre J, Arimidex Writing Committee, Steinberg M, Webster A, Sahmoud T, von Euler M, Thürlimann Beat, Robertson J F, Nabholtz J M, Buzdar A, Investigators Committee Members
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
Bonneterre J, Steinberg M, Webster A, Vergote I, Koralewski P, Mauriac L, Krzakowski M, Robertson J, Thürlimann B, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3748-57.
15.11.2000Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
15.11.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3748-57
Bonneterre J, Steinberg M, Webster A, Vergote I, Koralewski P, Mauriac L, Krzakowski M, Robertson J F, Thürlimann Beat, von Euler M